Preview

Systemic Hypertension

Advanced search

COVID-19: a patient with cardiovascular disease at high risk

https://doi.org/10.26442/2075082X.2020.2.200231

Abstract

The COVID-19 pandemic that has swept the planet has posed many questions for doctors around the world, including the tactics of managing patients with cardiovascular disease, both infected and self-isolated. A symposium held with the support of the Merck company was devoted to this problem: "COVID-19: a patient with cardiovascular pathology at a particular risk".

About the Authors

I. E. Chazova
Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology
Russian Federation


Y. V. Zhernakova
National Medical Research Center of Cardiology
Russian Federation


O. D. Ostroumova
Russian Medical Academy of Continuous Professional Education
Russian Federation


References

1. Российской медицинское общество по артериальной гипертонии. Рекомендации по ведению больных артериальной гипертонией с метаболическими нарушениями и сахарным диабетом 2-го типа. Системные гипертензии. 2020; 17 (1): 7-45

2. Bauters C, Lemesle G, Meurice T et al. Prognostic impact of b-blocker use in patients with stable coronary artery disease. Heart 2014; 100: 1757-61

3. Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019; 16 (1)

4. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 2018; 36 (10): 1953-2041. DOI: 10.1097/HJH.0000000000001940

5. Struijker-Boudier H et al. The Need for Combination Antihypertensive Therapy to Reach Target Blood Pressures: What Has Been Learned From Clinical Practice and Morbidity-Mortality Trials? Int J Clin Pract 2007; 61: 1592-602

6. Cruckshank JM. Are We Misunderstanding Beta-Blockers. Int J Cardiol 2007; 120: 10-27

7. Palatini P et al. Impact of Increased Heart Rate on Clinical Outcomes in Hypertension: Implications for Antihypertensive Drug Therapy. Drugs 2006; 66: 133-44

8. Murdoch D, Heel RC. Amlodipine. A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Cardiovascular Disease. Drugs 1991; 41 (3): 478-505. DOI: 10.2165/00003495-199141030-00009

9. Rana R, Patil A. Efficacy and safety of bisoprolol plus amlodipine fixed dose combination in essential hypertension. Indian Pract 2008; 61: 225-34

10. Parinello G, Paterna S, Torres D et al. One year Renal and Cardiac Effects of Bisoprolol versus Losartan in Recently Diagnosed Hypertensive Patients. Clin Drug Investigation 2009; 29: 591-600

11. Klein LW, Richard AD, Holt J et al Effects of chronic tobacco smoking on the coronary circulation. J Am Coll Cardiol 1983; 1 (2 Pt 2); 421-6

12. Cruickshank JM. The Modern Role of Beta-blockers in Cardiovascular Medicine. Shelton: CT Peoples Medical Publishing House-USA, 2011; Fig 3-32a

13. Buhler FR, Berglund G, Anderson OK et al. Double-blind comparison of cardioselective B-blockers bisoprolol and atenolol in in hypertension: the Bisoprolol International Multicenter Study (BIMS). J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): S 122-7


Review

For citations:


Chazova I.E., Zhernakova Y.V., Ostroumova O.D. COVID-19: a patient with cardiovascular disease at high risk. Systemic Hypertension. 2020;17(2):76-83. (In Russ.) https://doi.org/10.26442/2075082X.2020.2.200231

Views: 120


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2075-082X (Print)
ISSN 2542-2189 (Online)